There are 2789 resources available
373P - Brain metastases: Extracranial disease status as a prognostic factor after whole brain radiotherapy. Results from a prospective, population-based study
Presenter: Olav Yri
Session: ePoster Display
374P - A real-world application of aqueous humor and vitreous fluid for the diagnosis of vitreoretinal lymphoma and treatment monitoring
Presenter: Xiaoxiao Wang
Session: ePoster Display
375P - Clinical outcomes of targeting therapy with BRAF/MEK inhibitors in patients with BRAF V600-mutated brain tumors
Presenter: Marta Mejías Trueba
Session: ePoster Display
533P - Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
Presenter: Lyudmila Bazhenova
Session: ePoster Display
534P - Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
Presenter: Alexander Drilon
Session: ePoster Display
540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4
Presenter: David Hong
Session: ePoster Display
541P - Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours
Presenter: Maen Hussein
Session: ePoster Display
542P - Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours
Presenter: Manish Patel
Session: ePoster Display
464P - Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets
Presenter: Noelia Tarazona
Session: ePoster Display
465P - Identification of actionable alterations in primary colorectal tumors using NGS-based comprehensive genomic profiling
Presenter: Alfred KY Lam
Session: ePoster Display